ArticleBlood cancer journal2017

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.

L H Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.